The three-day forum will feature global leaders, scientists, regulatory body representatives, industry associations, and academia among many others
INDIA: BioAsia – the marquee healthcare and Life Sciences event, organized by the Government of Telangana, is all set for the grand unveiling of its 21st edition in Hyderabad. Sri Duddilla Sridhar Babu, Minister for Information Technology, Industries & Commerce conducted a comprehensive review of the preparations for the upcoming global conference. As the Flagship event of the Government of Telangana, BioAsia has emerged as a pivotal player in steering the life-sciences development journey in India, playing a crucial role in redirecting focus towards the advancements and challenges within the industry. The event is scheduled to be held between February 26 and 28, 2024 at the Hyderabad International Convention Center (HICC) in Hyderabad.
Distinctly, the 21st edition of BioAsia will feature prominent government dignitaries, industry leaders, researchers, entrepreneurs, and other delegates, and will explore the theme of Data & AI: Redefining Possibilities, to deliberate the possibility of reshaping the future of health tech delivery paradigm in the country. The event boasts a lineup of 70+ influential speakers, including global CEOs and industry leaders. Besides, the Keynote speakers already announced for the event including Mr. David Ricks (CEO, Eli Lilly, and Company), Dr. Christopher Boerner (Incoming CEO, Bristol Myers Squibb), Mr. Geoff Martha (Chairman and CEO, Medtronic), Prof. Gregg Semenza (Nobel Laureate & Professor at Johns Hopkins School of Medicine), among others, the event will also feature President and CEO, Olympus Mr. Stefan Kaufmann; CEO of Providence Dr. Rod Hochman, M.D., Global Operating Partner of Advent International Mr. Stefan Stoffel, among others.
With expectations soaring high with an extraordinary line-up of speakers, BioAsia 2024 is projected to attract over 3000 participants, offering a dynamic platform for networking and collaboration. Further, the event will have an increased exhibition this year with more than 200 companies set to showcase some of the most groundbreaking advancements and cutting-edge products. As the city welcomes numerous globally influential leaders, the event will provide a fertile ground for knowledge exchange and innovation in the life sciences and biotechnology sector. BioAsia 2024 will also offer a worldwide platform for promising startups in the pharmaceutical, biotech, life sciences, health-tech, and med-tech sectors to showcase their inventive concepts.
Sridhar Babu, Hon Minister for Industries & Commerce Dept., Government of Telangana, expressed his enthusiasm for the event’s growing global stature. He stated, “BioAsia has emerged as a critical instrument for the development of the Indian and global life science and allied industries over the last two decades. We are thrilled to announce that several global CEOs will be attending BioAsia for the first time, underlining the event’s rising prominence on the international stage. My team and I are leaving no stone unturned to ensure that BioAsia 2024 is grand and impactful. It’s not just an event; it’s a culmination of two decades of excellence. Together, let’s shape the future of healthcare”
Jayesh Ranjan, IAS, Principal Secretary, Industries & Commerce Dept., Government of Telangana, expressed his enthusiasm for the event’s growing global stature. He said, “Over the past 20 editions, BioAsia has played an unmatched role in sparking the renewed emphasis on the life-sciences industry, rekindling attention from regulation, corporates, startups, and allied sectors alike. “
“The 21st edition of BioAsia is certainly going to be a milestone event, as the presence of global leaders marks the vision to bridge the gaps in the healthcare industry and foster innovation in these critical sectors,” said Shakthi Nagappan, Director of Life Sciences, Govt. of Telangana and CEO of BioAsia.
The event, with EY as the knowledge partner, will focus on themes including Transformative innovation – R&D, Patent Paradox: India’s Bid for Global R&D Dominance & IP Dilemmas, Leading the Health-tech revolution – The Next Normal, India at the frontier of Pharma Services, MedTech is the place to be, etc. that are pertinent to the industry in the current times.
